ANI Pharmaceuticals
ANIP
71.93
+0.41
+0.57%
ANI Pharmaceuticals
US · ANIP
#2919 by market cap
Listed 1970
71.93
+0.41
+0.57%
Live - 5344 symbols - heartbeat 457s ago
· 2026-10-08 04:21
Pre-market
71.92
-0.01%
After-hours
72.15
+0.31%
- Market cap
- 1.65B
- P/E (TTM)i
- 15.67
- P/Bi
- 2.77
- EPSi
- 3.32
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on ANIP?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.27, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +43.78% YoY
Margins
- Gross margin
- 61.36%
- Operating margin
- 9.20%
- Net margin
- 7.95%
Key ratios & quality
- Enterprise valuei
- 1.97B
- Altman Z-Scorei
- 2.27
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 201.58M | 206.55M | 208.48M | 216.14M | 316.39M | 486.82M | 614.38M | 883.37M |
| Gross profit | 128.55M | 143.39M | 121.32M | 115.53M | 177.60M | 305.30M | 364.17M | 542.06M |
| Selling & admin expenses | 44.06M | 55.84M | 64.99M | 84.29M | 124.04M | 161.70M | 249.64M | 317.75M |
| Research & development | 15.39M | 19.81M | 16.00M | 11.37M | 22.32M | 34.29M | 44.58M | 51.66M |
| Operating profit | 35.36M | 16.43M | -15.57M | -28.17M | -25.73M | 49.53M | 2.22M | 81.23M |
| Pretax profit | 20.05M | 3.16M | -25.96M | -56.06M | -62.67M | 19.87M | -22.21M | 95.79M |
| Tax | 4.56M | -2.94M | -3.41M | -13.46M | -14.77M | 1.09M | -3.69M | 17.45M |
| Net profit | 15.49M | 6.09M | -22.55M | -42.60M | -47.90M | 18.78M | -18.52M | 78.34M |
| Basic EPS | 1 | 1 | -2 | -3 | -3 | 1 | -1 | 4 |
| Diluted EPS | 1.30 | 0.50 | -1.88 | -3.40 | -3.05 | 0.85 | -1.04 | 3.32 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 197.12M | 211.37M | 227.81M | 247.06M | 237.46M | 266.04M |
| Gross profit | 124.09M | 136.76M | 134.42M | 146.79M | 143.88M | 165.89M |
| Selling & admin expenses | 76.53M | 81.77M | 76.66M | 82.79M | 73.66M | 91.66M |
| Research & development | 10.56M | 16.54M | 12.30M | 12.26M | 10.60M | 14.75M |
| Operating profit | 14.10M | 15.17M | 22.83M | 29.13M | 38.71M | 39.84M |
| Pretax profit | 19.99M | 10.53M | 33.80M | 31.48M | 40.22M | 37.10M |
| Tax | 4.31M | 1.98M | 7.18M | 3.99M | 10.73M | 12.39M |
| Net profit | 15.68M | 8.55M | 26.62M | 27.49M | 29.49M | 24.71M |
| Basic EPS | 1 | 0 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.69 | 0.36 | 1.13 | 1.18 | 1.28 | 1.05 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 152.88M | 187.70M | 170.32M | 321.78M | 344.26M | 519.82M | 528.46M | 753.12M |
| Cash & ST investments | 43.01M | 62.33M | 7.86M | 100.30M | 48.23M | 221.12M | 151.17M | 294.72M |
| Inventory | 40.50M | 48.16M | 60.80M | 81.69M | 105.36M | 111.20M | 136.78M | 143.07M |
| Total assets | 430.60M | 456.79M | 461.19M | 771.60M | 760.09M | 904.42M | 1.28B | 1.44B |
| Total current liabilities | 165.55M | 61.68M | 78.57M | 87.54M | 99.44M | 145.48M | 194.45M | 278.11M |
| Short-term debt | 115.72M | 9.94M | 13.24M | 850.00K | 850.00K | 850.00K | 9.17M | 17.27M |
| Long-term debt | 67.30M | 175.81M | 172.44M | 286.52M | 285.67M | 284.82M | 614.92M | 599.77M |
| Total liabilities | 233,341,000.00 | 243,998,000.00 | 265,490,000.00 | 412,858,000.00 | 421,547,000.00 | 446,823,000.00 | 855,939,000.00 | 899,653,000.00 |
| Total equity | 197.26M | 212.79M | 195.70M | 358.74M | 338.54M | 457.60M | 428.53M | 540.72M |
| Retained earnings | 11.49M | 17.58M | -4.97M | -47.77M | -97.29M | -80.13M | -100.28M | -23.10M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 536.29M | 602.63M | 698.40M | 753.12M | 747.08M | 825.43M |
| Cash & ST investments | 155.19M | 223.52M | 271.47M | 294.72M | 326.06M | 375.84M |
| Inventory | 137.41M | 138.32M | 146.48M | 143.07M | 143.47M | 143.15M |
| Total assets | 1.29B | 1.34B | 1.41B | 1.44B | 1.42B | 1.49B |
| Total current liabilities | 201.82M | 236.84M | 270.56M | 278.11M | 239.51M | 283.66M |
| Short-term debt | 11.19M | 13.22M | 15.24M | 17.27M | 19.30M | 21.33M |
| Long-term debt | 611.63M | 608.35M | 605.07M | 599.77M | 594.46M | 589.16M |
| Total liabilities | 848,958,000.00 | 881,394,000.00 | 902,335,000.00 | 899,653,000.00 | 859,670,000.00 | 896,900,000.00 |
| Total equity | 443.47M | 461.61M | 505.82M | 540.72M | 562.30M | 597.21M |
| Retained earnings | -85.00M | -76.86M | -50.59M | -23.10M | 6.39M | 31.10M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 67.07M | 45.63M | 15.27M | 3.32M | -31.20M | 118.96M | 64.02M | 185.23M |
| Depreciation & amortization | 33.74M | 44.61M | 44.64M | 47.25M | 59.65M | 59.79M | 67.73M | 91.42M |
| Free cash flow | 56.16M | 18.08M | -53.06M | -20.32M | -47.66M | 100.45M | 47.06M | 150.90M |
| Dividends paid | -- | 0 | 0 | -190.00K | -1.63M | -1.63M | -1.63M | -1.16M |
| Stock buybacks / issuance | -659.00K | -1.03M | -1.52M | 68.69M | -1.96M | 75.57M | -10.96M | -12.21M |
| Ending cash balance | 48.03M | 67.36M | 12.87M | 105.30M | 53.23M | 221.12M | 144.89M | 285.62M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 34.99M | 75.81M | 44.06M | 30.37M | 58.38M | 56.67M |
| Depreciation & amortization | 22.89M | 23.28M | 22.63M | 22.61M | 20.92M | 19.64M |
| Free cash flow | 15.15M | 68.90M | 37.89M | 28.96M | 47.05M | 53.62M |
| Dividends paid | -406.00K | -407.00K | -344.00K | 0 | 0 | 0 |
| Stock buybacks / issuance | -10.00M | -- | -- | -- | -19.76M | -- |
| Ending cash balance | 149.84M | 217.83M | 262.65M | 285.62M | 311.21M | 360.25M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 8.25 | 2.97 | -11.04 | -16.16 | -15.29 | 4.60 | -4.82 | 14.87 |
| ROA %i | 3.64 | 1.37 | -4.91 | -6.94 | -6.47 | 2.06 | -1.84 | 5.16 |
| ROIC %i | 7.07 | 4.00 | -3.68 | -6.73 | -4.60 | 6.46 | -0.63 | 7.93 |
| 5-year avg ROE %i | 10.37 | 4.63 | 0.39 | -3.32 | -6.26 | -7.08 | -8.63 | -3.45 |
| EBIT margin %i | 17.27 | 7.81 | -7.92 | -20.42 | -10.94 | 9.62 | -0.75 | 13.11 |
| FCF / sales %i | 27.86 | 8.75 | -- | -- | -- | 20.63 | 7.66 | 17.08 |
| Current ratioi | 0.92 | 3.04 | 2.17 | 3.68 | 3.46 | 3.57 | 2.72 | 2.71 |
| Quick ratioi | 0.65 | 2.18 | 1.32 | 2.61 | 2.15 | 2.63 | 1.92 | 2.07 |
| Debt / assetsi | 42.50 | 40.66 | 40.26 | 37.24 | 37.70 | 31.59 | 48.59 | 42.84 |
| LT debt / equityi | 34.11 | 82.62 | 88.12 | 85.81 | 91.07 | 65.82 | 152.33 | 110.92 |
| Interest coveragei | 2.36 | 1.24 | -1.75 | -3.70 | -1.23 | 1.74 | -0.26 | 5.78 |
| Revenue CAGR (3Y) %i | 38.23 | 17.10 | 5.64 | 2.35 | 15.27 | 32.67 | 41.66 | 40.81 |
| Net income CAGR (3Y) %i | 0.26 | 15.71 | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -5.21 | -2.65 | 8.56 | 14.87 | 17.22 | 19.27 |
| ROA %i | -2.05 | -1.05 | 2.89 | 5.16 | 6.22 | 7.02 |
| ROIC %i | -0.96 | 0.17 | 5.23 | 7.93 | 8.93 | 9.90 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1.35 | 0.60 | 8.73 | 13.11 | 14.55 | 16.27 |
| FCF / sales %i | 7.20 | 13.98 | 16.37 | 17.08 | 19.79 | 17.12 |
| Current ratioi | 2.66 | 2.54 | 2.58 | 2.71 | 3.12 | 2.91 |
| Quick ratioi | 1.86 | 1.90 | 1.94 | 2.07 | 2.43 | 2.29 |
| Debt / assetsi | 48.19 | 46.28 | 44.05 | 42.84 | 43.16 | 40.86 |
| LT debt / equityi | 146.11 | 139.29 | 119.62 | 110.92 | 105.72 | 98.65 |
| Interest coveragei | -0.49 | 0.23 | 3.33 | 5.78 | 7.32 | 9.62 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Rare Disease and Brands is the largest reported line at 62.17% of revenue, across 2 reported segments.
- Generics and Other follows at 37.83%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Rare Disease and Brands62.17%
Generics and Other37.83%
Quote time 2026-10-08 04:21:51 · For reference only, not investment advice and not tailored to your situation.